Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points

Abstract Venetoclax (VEN), a small-molecule inhibitor of B cell leukemia/lymphoma-2, is now FDA approved (November 2018) for use in acute myeloid leukemia (AML), specific to newly diagnosed elderly or unfit patients, in combination with a hypomethylating agent (HMA; including azacitidine or decitabi...

Full description

Bibliographic Details
Main Authors:	Naseema Gangat, Ayalew Tefferi
Format:	Article
Language:	English
Published:	Nature Publishing Group 2020-11-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-020-00388-x

Similar Items

Venetoclax-containing regimens in acute myeloid leukemia
by: Ibrahim Aldoss, et al.
Published: (2021-02-01)

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
by: Guillaume Richard-Carpentier, et al.
Published: (2019-10-01)

Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm
by: Coen J. Lap, et al.
Published: (2021-01-01)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
by: Bachar Samra, et al.
Published: (2020-11-01)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

OBATOCLAX REDUCES CELL VIABILITY OF ACUTE MYELOID LEUKEMIA CELLS INDEPENDENTLY OF THEIR SENSITIVITY TO VENETOCLAX
by: K. Lima, et al.
Published: (2020-11-01)

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome
by: Mohammad Houshmand, et al.
Published: (2021-03-01)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
by: Rie Nishi, et al.
Published: (2020-10-01)

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)
by: Heather Klocke, et al.
Published: (2020-01-01)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
by: Knight T, et al.
Published: (2019-04-01)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
by: Maansi Joshi, et al.
Published: (2021-03-01)

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
by: Di Wu, et al.
Published: (2021-01-01)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine
by: Chyla, B., et al.
Published: (2022)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
by: Nerea Báez-Gutiérrez, et al.
Published: (2021-08-01)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
by: Abhishek Maiti, et al.
Published: (2021-02-01)

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
by: Xiang Zhang, et al.
Published: (2021-05-01)

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
by: Ralf Buettner, et al.
Published: (2021-04-01)

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
by: Jayna J Mistry, et al.
Published: (2021-05-01)

Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach
by: Arber, D.A, et al.
Published: (2022)

Screening for an underlying myeloproliferative neoplasm in patients with thrombocytosis post-induction chemotherapy for acute myeloid leukemia
by: Stephen E. Langabeer
Published: (2020-01-01)

Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner
by: Shujuan Huang, et al.
Published: (2020-10-01)

Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
by: Hyunsoo Cho, et al.
Published: (2021-04-01)

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
by: Kaiqi Liu, et al.
Published: (2021-09-01)

Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature
by: Nil Albiol, et al.
Published: (2021-06-01)

VENETOCLAX FOR RELAPSED ACUTE MYELOID LEUCEMIA AS A “BRIDGE FOR ALLOGENEIC HEMATOPOEITIC STEM CELL TRANSPLANT”: A CASE REPORT
by: A.P. Udo, et al.
Published: (2020-11-01)

Mayo Clinic experience with 1123 adults with acute myeloid leukemia
by: Kebede H. Begna, et al.
Published: (2021-03-01)

Azacitidine combined with low dose Venetoclax and Azole in treatment-naive, elderly patient with acute myeloid leukemia: A case report
by: Jean Zeghondy, et al.
Published: (2020-09-01)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
by: Matthew E. Tenold, et al.
Published: (2021-03-01)

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature
by: Nosha Farhadfar, et al.
Published: (2021-09-01)

Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination
by: Daniela Taurino, et al.
Published: (2021-08-01)

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
by: Ravendra Garg, et al.
Published: (2021-02-01)

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
by: Matteo Piccini, et al.
Published: (2021-04-01)

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
by: Aleksina Shatilova, et al.
Published: (2021-05-01)

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
by: Carmen D. Herling, et al.
Published: (2018-02-01)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
by: Schieber M, et al.
Published: (2019-03-01)

Hodgkin Lymphoma as a Secondary Neoplasm During Therapy for Chronic Myeloid Leukaemia: Case Report and Review of the Literature
by: Paczkowska E, et al.
Published: (2021-04-01)

SET-CAN Fusion Gene in Acute Leukemia and Myeloid Neoplasms: Report of Three Cases and a Literature Review
by: Zhang H, et al.
Published: (2020-08-01)

THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA
by: Francesca Ricci, et al.
Published: (2011-07-01)

THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA
by: Alessandra Tedeschi, et al.
Published: (2011-01-01)

Familial Myelodysplastic/Acute Leukemia Syndromes—Myeloid Neoplasms with Germline Predisposition
by: Renata Lyrio Rafael Baptista, et al.
Published: (2017-09-01)